The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase by unknown
Maciejak et al. BMC Biotechnology 2013, 13:68
http://www.biomedcentral.com/1472-6750/13/68RESEARCH ARTICLE Open AccessThe effects of statins on the mevalonic acid
pathway in recombinant yeast strains expressing
human HMG-CoA reductase
Agata Maciejak1†, Agata Leszczynska1†, Ilona Warchol1, Monika Gora1, Joanna Kaminska1, Danuta Plochocka1,
Monika Wysocka-Kapcinska1, Dorota Tulacz1, Joanna Siedlecka1, Ewa Swiezewska1, Maciej Sojka2,
Witold Danikiewicz2, Norbert Odolczyk1, Anna Szkopinska1, Grazyna Sygitowicz3 and Beata Burzynska1*Abstract
Background: The yeast Saccharomyces cerevisiae can be a useful model for studying cellular mechanisms related to
sterol synthesis in humans due to the high similarity of the mevalonate pathway between these organisms. This
metabolic pathway plays a key role in multiple cellular processes by synthesizing sterol and nonsterol isoprenoids.
Statins are well-known inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), the key enzyme of the
cholesterol synthesis pathway. However, the effects of statins extend beyond their cholesterol-lowering action, since
inhibition of HMGR decreases the synthesis of all products downstream in the mevalonate pathway. Using
transgenic yeast expressing human HMGR or either yeast HMGR isoenzyme we studied the effects of simvastatin,
atorvastatin, fluvastatin and rosuvastatin on the cell metabolism.
Results: Statins decreased sterol pools, prominently reducing sterol precursors content while only moderately
lowering ergosterol level. Expression of genes encoding enzymes involved in sterol biosynthesis was induced, while
genes from nonsterol isoprenoid pathways, such as coenzyme Q and dolichol biosynthesis or protein prenylation,
were diversely affected by statin treatment. Statins increased the level of human HMGR protein substantially and
only slightly affected the levels of Rer2 and Coq3 proteins involved in non-sterol isoprenoid biosynthesis.
Conclusion: Statins influence the sterol pool, gene expression and protein levels of enzymes from the sterol and
nonsterol isoprenoid biosynthesis branches and this effect depends on the type of statin administered. Our model
system is a cheap and convenient tool for characterizing individual statins or screening for novel ones, and could
also be helpful in individualized selection of the most efficient HMGR inhibitors leading to the best response and
minimizing serious side effects.
Keywords: HMG-CoA reductase, Statins, Yeast expression system, Heterologous proteins, Mevalonate pathwayBackground
The mevalonic acid pathway (MVA, Figure 1) leads
to the synthesis of sterol isoprenoids, with the final
product cholesterol (ergosterol in yeast), and nonsterol
isoprenoids, such as dolichols, the side chain of ubi-
quinone, farnesyl diphosphate (FPP) and geranylgeranyl
diphosphate (GGPP). Statins are well-known inhibitors
of 3-hydroxy-3-methylglutaryl-coenzyme A reductase* Correspondence: atka@ibb.waw.pl
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reproduction in any medium, provided the or(HMGR). This group of drugs is widely used in the
treatment of hyperlipidemia and cardiovascular diseases
[1-3]. However, the effects of statins extend beyond their
cholesterol-lowering action. Inhibition of HMG-CoA re-
ductase, the regulatory enzyme of the pathway, results in
disturbances in practically all vital cellular processes,
such as protein glycosylation and prenylation, cell sig-
naling, functioning of the respiratory chain and integrity
of cellular membranes [4]. The impairment of these pro-
cesses may contribute to the pleiotropic side-effects of
statins [5-7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The mevalonate pathway. The enzymes selected for gene expression analysis are shown at the corresponding steps of the pathway.
The dashed lines indicate multicomponent pathways. ERG10 – acetyl-CoA acetyltransferase, ERG13 – 3-hydroxy-3-methylglutaryl-CoA synthase,
human (HMGR) and yeast (HMG1, HMG2) 3-hydroxy-3-methylglutaryl-Co A reductase 1 and 2, FPP1 – farnesyl pyrophosphate synthase,
ERG1 – squalene monooxygenase, ERG6 – delta(24)-sterol C-methyltransferase, ERG3 – C-5 sterol desaturase, COQ3 – 3,4-dihydroxy-5-
hexaprenylbenzoatemethyltransferase, COQ2 – para-hydroxybenzoate-polyprenyl transferase, CAT5 – ubiquinone biosynthesis monooxygenase,
BTS1 – geranylgeranyl diphosphate synthase, RER2 – cis-prenyltransferase, SEC59 – dolichol kinase.
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for studying metabolic pathways and cellular mecha-
nisms of human diseases as it is genetically tractable
and shares many similarities with human cells [8]. As a
eukaryote, S. cerevisiae has many of the advantages of
higher eukaryotic expression systems such as protein
processing, protein folding and posttranslational modifi-
cations, at the same time being as easy to manipulate as
are bacteria. The use of yeast as a model of fundamental
cellular processes and metabolic pathways of the human
has improved the understanding and facilitated the mo-
lecular analysis of many disease-related genes. Compara-
tive genomics studies have shown that 40% of yeast
proteins have at least one human homolog and 30% of
genes involved in human disease pathology have an
ortholog in yeast [9]. Also, many regulatory pathways
are conserved between yeast and humans. For example,
the use of recombinant yeast to screen for new inhibi-
tors of human acetyl-CoA carboxylase has led to thediscovery of potential drugs to treat obesity [10]. The
mevalonate pathways in yeast and humans are highly
similar. All the steps from HMG-CoA formation to
zymosterol synthesis are biochemically the same. The
high degree of conservation of the mevalonate path-
way – from unicellular organisms to human cells –
justifies the use of S. cerevisiae to study the general
principles of this pathway and its response to drugs [9].
Here, we investigated the effects of four statins widely
used in the clinical practice – simvastatin, atorvastatin,
fluvastatin and rosuvastatin – on the growth rate and
metabolism of yeast cells. Three yeast strains were
constructed to express human HMGR or either of the
yeast isoenzymes. We examined the levels of ergoste-
rol – the yeast cholesterol analog – and its precursors
after statin treatment. We also investigated the statin-
induced changes in the expression of genes from the
nonsterol branches of the MVA pathway such as those
involved in ubiquinone and dolichol biosynthesis and in
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the expression of genes encoding enzymes of the sterol
biosynthesis pathway was analysed by real-time PCR.
The effects of statins on the levels of selected proteins
from those pathways were investigated by Western blot-
ting. Finally, we evaluated the effects of the individual
statins on the mevalonate and associated pathways.
Results
The effects of statins on yeast growth
In this study we used a yeast expression system de-
scribed earlier [11]. Here we applied the following
strains:
 H – yeast strain with double hmg1Δ hmg2Δ deletion
(i.e., completely devoid of native HMGR activity)
transformed with a plasmid carrying the human
HMGR gene.
 Y1 – double hmg1Δ hmg2Δ deletion yeast strain
transformed with a plasmid carrying yeast HMG1
gene.
 Y2 – double hmg1Δ hmg2Δ deletion yeast strain
transformed with a plasmid carrying yeast HMG2
gene.
Since the HMG-CoA reductase activity is essential for
yeast growth, we could investigate the relative sensitivity
of the human HMGR to the various statins by compar-
ing the growth kinetics of appropriate recombinant yeast
strains in the presence of different concentrations of the
statins. Based on OD600 readings growth curves were
plotted for each culture. For further research we chose
the concentration of 100 μM for all statins, which was
the highest non-toxic dose for yeast cells.
As shown in Figure 2, statins exerted different effects
on the yeast strains tested. The strongest inhibitory ef-
fect on yeast growth was observed in cultures supple-
mented with fluvastatin. Atorvastatin and rosuvastatin
caused milder yeast growth inhibition, whereas simva-
statin only slightly affected yeast growth.
Quantification of mRNA for genes encoding selected
enzymes from the sterol and nonsterol branches of the
isoprenoid biosynthesis pathways
The effects of statins on the level of expression of genes
encoding enzymes involved in isoprenoid biosynthesis
were investigated for selected enzymes whose homologs
can be found both in yeast and human cells. These
included:
 genes from the mevalonate pathway: acetyl-CoA
acetyltransferase (ERG10), hydroxymethylglutaryl-
CoA synthase (ERG13), human (HMGR) and yeast
(HMG1, HMG2) 3-hydroxy-3-methylglutaryl-coenzyme A reductase, farnesyl diphosphate
synthase (ERG20, FPP1).
 sterol-specific genes encoding enzymes involved in
sterol biosynthesis: squalene monooxygenase
(ERG1), C-5 sterol desaturase (ERG3) and,
additionally, the gene coding for delta(24)-sterol C-
methyltransferase (ERG6), an enzyme absent in
humans (the encoded enzyme converts zymosterol
to fecosterol in the pathway leading to ergosterol,
the principal sterol in fungi).
 nonsterol-specific genes encoding enzymes involved
in ubiquinone biosynthesis: para-hydroxybenzoate-
polyprenyl transferase (COQ2), 3,4-dihydroxy-5-
hexaprenylbenzoate-O-methyltransferase (COQ3)
and ubiquinone biosynthesis monooxygenase
(CAT5); dolichol synthesis: cis-prenyltransferase
(RER2) and dolichol kinase (SEC59); and protein
prenylation: geranylgeranyl diphosphate synthase
(BTS1).
In general, the statins induced expression of the genes
from the mevalonate pathway and its sterol-specific
branch, although the magnitude of the stimulation dif-
fered greatly between the genes, and for a given gene,
between the four statins (Figure 3A). In the H strain
carrying human HMGR the strongest effect was ob-
served after simvastatin treatment, except for the human
HMGR gene itself, whose expression was induced to the
highest degree after rosuvastatin treatment.
In contrast, statins caused highly divergent changes in
the expression of genes coding for the enzymes from the
ubiquinone synthesis (COQ2, COQ3, CAT5), dolichol
synthesis (RER2, SEC59) and protein prenylation (BTS1)
pathways (Figure 3B). In strain H expression of all those
genes was reduced by simvastatin, atorvastatin and flu-
vastatin. Interestingly, rosuvastatin caused a diverse ef-
fect: expression of three genes (BTS1, COQ3 and RER2)
was induced, and three other genes (COQ2, CAT5 and
SEC59) responded with a slight decrease of expression.
In the Y1 and Y2 strains expression of those genes was
generally reduced, except for the COQ3 gene. Notably,
in the Y1 strain rosuvastatin induced the expression of
all the tested genes. A striking conclusion from this part
of the study is that the effects of rosuvastatin on the ex-
pression of genes from the nonsterol isoprenoid path-
ways are clearly different from those of the other statins,
regardless of the yeast strain investigated. In the strain
carrying human HMGR the action of rosuvastatin is
more ‘positive’: it is either the strongest, or the only in-
ducer of expression, or the weakest repressor.
The level of selected proteins after statin treatment
In parallel to the transcript analysis Western blotting
was applied to follow the cellular levels of corresponding
Figure 2 Statins inhibit growth of yeast strains. Growth kinetics of yeast strains cultured in liquid minimal media supplemented with either
statins or buffer. OD600 of each culture was measured at intervals. Data represent mean ± SD of triplicate experiments. When the error bars are
absent; SD falls within the size of symbols. B – buffer, S – simvastatin, A – atorvastatin, F – fluvastatin, R – rosuvastatin.
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HMGR protein was higher after statin treatment com-
pared to the control. The magnitude of that effectdepended on the type of statin used: the lowest accumu-
lation was observed after simvastatin treatment (about
2.4-fold) and the highest one – in the presence of
Figure 3 Statins induce expression of genes encoding enzymes of sterol and nonsterol biosynthesis pathways. mRNA levels in statin-
treated cells relative to control (buffer-treated cells) are shown using log2 scale. Results are mean ± SEM obtained by qRT-PCR. *p < 0.05, ***p <
0.001. Real-time PCR data, were normalize to 35S rRNA, a housekeeping gene. S – simvastatin, A – atorvastatin, F – fluvastatin, R – rosuvastatin.
A) Quantitative real-time RT-PCR analysis of selected genes encoding enzymes of sterol biosynthesis pathway after statin treatment compared to
buffer-treated cells. ERG10 – acetyl-CoA acetyltransferase, ERG13 – 3-hydroxy-3-methylglutaryl-CoA synthase, HMGR – human 3-hydroxy-3-
methylglutaryl-Co A reductase, HMG1 and HMG2 – yeast 3-hydroxy-3-methylglutaryl-Co A reductase 1 and 2, FPP1 – farnesyl pyrophosphate
synthase, ERG1 – squalene monooxygenase, ERG6 – delta(24)-sterol C-methyltransferase, ERG3 – C-5 sterol desaturase. B) Quantitative real-time
RT-PCR analysis of genes from ubiquinone and dolichol synthesis and protein prenylation pathways. CAT5 – ubiquinone biosynthesis
monooxygenase, COQ3 – 3,4-dihydroxy-5-hexaprenylbenzoate-O-methyltransferase, COQ2 – para-hydroxybenzoate-polyprenyl transferase,
BTS1 – geranylgeranyl diphosphate synthase, RER2 – cis-prenyltransferase, SEC59 – dolichol kinase.
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crease of the human HMGR protein level after statin
treatment, the levels of the nonsterol pathway proteins,
Rer2 and Coq3, were only slightly changed in response
to the statins. In general, the response of those two en-
zymes at the protein level correlated well with the effects
of the statins on their mRNA levels.
Efficiency of individual statins in decreasing the level of
sterols
To investigate the effects of various statins on yeast cell
sterol levels, the H strain was treated with the fourstatins or buffer, sterols were isolated and submitted to
GC/MS analysis. The levels of ergosterol and its precur-
sors squalene, lanosterol, zymosterol and fecosterol, as
well as the total amount of identified sterols, were calcu-
lated. In statin-treated cells the total sterol pool and the
levels of each sterol precursor identified were lower than
in control cells (Table 1). The most prominent decrease
was noted for squalene, the content of which was bet-
ween 24% (after atorvastatin) and 7% (after fluvastatin)
of its content in control cells. Of the sterols measured,
the level of ergosterol was the least diminished (to bet-
ween 13% of the control level after simvastatin and 54%
Figure 4 Statins affect levels of human HMGR and yeast Rer2
and Coq3 proteins. Strains expressing GFP-HMGR, HA-Rer2 or
Coq3-HA proteins were grown for 24 hours in the presence of
buffer (B) or one of the statins: atorvastatin (A), fluvastatin (F),
rosuvastatin (R) or simvastatin (S). Protein extracts were prepared
and analyzed by Western blotting. The level of plasma membrane
ATPase Pma1p is shown as a loading control. A) Steady state level
of human HMGR is higher after statin treatment with the highest
increase after rosuvastatin treatment. Western blot was analyzed
with anti-GFP or, for loading control, anti-Pma1 antibody. Ratio
of respective signals is shown below. B) Levels of yeast Rer2
and Coq3 proteins are marginally affected by statin treatment.
Western blots were analyzed with anti-HA or, for loading control,
anti-Vma2 antibody.
Table 1 Levels of sterols and squalene after statin









Squalene 14 24 7 9
Lanosterol 10 23 12 12
Zymosterol 7 50 19 41
Fecosterol 7 22 15 16
Ergosterol 13 37 39 54
Total 13 33 27 39
Data expressed as percentage of the amounts found in control
(buffer–treated) cells.
Maciejak et al. BMC Biotechnology 2013, 13:68 Page 6 of 11
http://www.biomedcentral.com/1472-6750/13/68after rosuvastatin). The four statins differed substantially
in their overall inhibitory effects on sterol synthesis.
Simvastatin exerted the strongest inhibitory effect (total
sterol pool reduced to 13% of the control level) androsuvastatin the mildest (total sterols lowered to 39% of
the control).
Discussion
The use of yeast as a model organism for studying cell
biology and a host for the expression of heterologous
proteins is becoming increasingly popular in recent years
[12,13]. In this study a yeast expression system was
applied to investigate the effects of four statins widely
used in the clinical practice – simvastatin, atorvastatin,
fluvastatin and rosuvastatin – on a number of cellular
processes. First, the effects of the statins on yeast growth
were checked. The strongest inhibitory effect was
exerted by fluvastatin, milder effects were noted for ator-
vastatin and rosuvastatin, whereas simvastatin did not
significantly affect yeast growth. Those results suggest
that at the dose used fluvastatin is the most toxic while
simvastatin is the safest of the HMGR inhibitors tested.
As statins are mainly prescribed to hypercholesterol-
emic patients to normalize the levels of serum lipopro-
teins, we focused on expression of the genes related to
sterol biosynthesis. A comparative analysis of expression
of genes from the mevalonate pathway (ERG10, ERG13,
HMG1 and HMG2, FPP1) as well as sterol-specific genes
encoding enzymes involved in sterol biosynthesis (ERG1,
ERG3 and, ERG6) revealed increased mRNA levels for
most of those genes in response to statins. Statins also
induced the expression of the HMGR-encoding genes
(human HMGR, yeast HMG1 and HMG2) in the re-
spective strains. However, the magnitude of the response
varied substantially between the four statins and also be-
tween the strains. In the H strain expressing human
HMGR, simvastatin was the strongest inducer of all the
above genes except for human HMGR itself, for which it
was the weakest inducer of all the statins assayed. Our
results indicate that the HMGR inhibitors affect the ex-
pression of practically all enzymes of the sterol branch
of the mevalonate pathway and this effect depends on
the type of statin administered but also, rather unexpec-
tedly, on the type of HMGR expressed in the cell.
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velop an adaptive response compensating for the dimin-
ished level of sterols which include increased expression
of mevalonate pathway genes. Similar results were ob-
served in human skeletal muscle-like cells [14] and
human hepatoma HepG2 cells [15]. In those studies
statins increased the expression of numerous cholesterol
synthesis-related genes. This is in accordance with the
results of Gerber et al. [16], Hagemenas and Illingworth
[17] and ours [18] proving that inhibition of HMGR ac-
tivity by statin treatment stimulates an adaptive response
in the cell in order to maintain sterol homeostasis, in-
cluding up-regulation of genes involved in cholesterol
biosynthesis, a compensatory increase in HMGR level
and consequent partial reduction of the sterol lowe-
ring effect.
To investigate whether statins produce similar effects
on the expression of genes involved in pathways bran-
ching off the main sterol biosynthesis pathway we chose
six genes involved in ubiquinone synthesis (COQ2,
COQ3 and CAT5), dolichol synthesis (RER2, SEC59) or
protein prenylation (BTS1). Surprisingly, the effects of
statins on the expression of those genes were unlike
those discussed above for the main pathway. Highly di-
vergent changes in the expression of the genes tested
were noted after statin treatment, with the majority
showing reduced level of transcripts.
Our mRNA quantification results show that statins
generally decrease expression of ubiquinone synthesis-
related genes in the H strain (CAT5, COQ2, COQ3). The
strongest such decrease was noted in yeast cells treated
with atorvastatin. Experimental data showed that atorva-
statin significantly decreases the coenzyme Q level in
the blood of patient at risk for cardiovascular disease
and stroke [19,20]. Ample studies have demonstrated
that, as a consequence of HMG-CoA reductase inhib-
ition, statins block the production of farnesyl diphos-
phate (FPP), serving as substrate for, among others, the
synthesis of the side chain of ubiquinone. The direct ef-
fect through FPP depletion may not be the only mechan-
ism whereby statins lower CoQ synthesis.
Next, we checked the effects of statins on the expres-
sion of genes encoding yeast cis-prenyltransferase Rer2p
and dolichol kinase Sec59p. In our study statins ge-
nerally reduced expression of RER2 and SEC59 genes,
which suggests that the dolichol synthesis could be de-
creased in statin-treated cells. Polyprenols and dolichols
(polyisoprenoid alcohols with saturated α-residue) are
long-chain highly hydrophobic lipids broadly distributed
in all tissues and cellular membranes of eukaryotic cells.
Moreover, dolichol affects the structure and fluidity of
the cellular membrane and probably also influence the
activity of membrane-associated proteins [21] or protect
components of biological membranes against oxidativestress [22]. Dolichol has also been shown to delay the
G1 cell cycle arrest in human fibroblasts [23]. Further-
more, dolichol plays a role in the regulation of angioge-
nesis during tumor growth [24].
In the protein prenylation branch we observed a sig-
nificantly increased geranylgeranyl diphosphate synthase
(BTS1) mRNA level after rosuvastatin treatment. Protein
prenylation is crucial for global cellular functions such
as proliferation, differentiation, apoptosis and carcino-
genesis. It requires the 15-carbon isoprenoid farnesyl
diphosphate (FPP) or the 20-carbon geranylgeranyl di-
phosphate (GGPP), both of which are intermediates of
the MVA pathway. Prenylated Rho and Rac proteins are
potent negative regulators of endothelial nitric oxide
synthase (eNOS). By inhibition of geranylgeranylation
statins were found to inactivate the Rho and Rac pro-
teins, causing eNOS up-regulation and subsequent NO
release [25]. Moreover, inhibition of Rac1 protein in the
course of statin therapy accounted for a decreased devel-
opment of cardiac hypertrophy [26].
Western blotting analysis showed clearly that statin
treatment increases the steady state level of human
HMGR protein in the H strain of yeast. The strongest
increase was observed in rosuvastatin-treated cells,
which is in accordance with the results of the gene ex-
pression analysis which showed the highest induction of
human HMGR gene expression after rosuvastatin treat-
ment. In contrast to the substantial increase of the hu-
man HMGR protein level after statin treatment, the
levels of Rer2 and Coq3 proteins were only slightly
changed in statin-treated cells. The response of Rer2 and
Coq3 proteins is similar to the changes of the their tran-
scripts level after statins treatment.
HMG-CoA reductase inhibitors are highly potent at
lowering LDL cholesterol. Here, statins substantially
lowered the level of ergosterol and (in most instances)
much more strongly the levels of all its triterpene pre-
cursors (Table 1). This is in accordance with the results
of Fowler et al. [27] showing a profound decrease of er-
gosterol level and an even deeper depletion of its precur-
sors in lovastatin-treated yeast cells. Both these results
indicate that following HMGR inhibition the yeast cell,
whether it expresses the native enzyme [27] or the
human one (this work), increases the rate of precursor
conversion into ergosterol in an attempt to maintain the
supply of this vital sterol. It remains to be shown
whether the same is also true of human cells. If so, the
inhibition of HMGR by statins would result in a deeper
depletion of cholesterol precursors than of cholesterol it-
self. Such a disproportionately profound depletion could
possibly account for some of the adverse effects of statin
therapy [28].
In our study simvastatin caused the strongest re-
duction in the content of sterols in the strain carrying
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lates with the gene expression results which showed the
strongest overexpression of genes encoding selected en-
zymes from the sterol-specific branch after simvastatin
treatment in the H strain. On the other hand, rosu-
vastatin differed from the other statins in its effect on
the mRNA level of nonsterol-specific genes. In the strain
carrying human HMGR expression of genes from non-
sterol isoprenoid biosynthesis branches was strongly
reduced after simvastatin, atorvastatin and fluvastatin
treatment, while rosuvastatin caused only a mild repres-
sion or, for some of those genes, even a substantial in-
duction. Taken together, this proves that statins,
although classified to the same therapeutic group, differ
strikingly in terms of their potency of action on the cell
metabolism.
It may be assumed that statins affect the cell on sev-
eral metabolic levels. The presented data suggest that in-
hibition of HMGR activity by statins stimulates an
adaptive response in the cell, including up-regulation of
genes involved in sterol biosynthesis. Genes from the
pathways branching off the sterol-synthesis route appear
to be less susceptible to the up-regulation, possibly be-
cause the levels of substrates for their enzymes are lower
after statin treatment. Moreover, the diverse effects ob-
served for individual HMGR inhibitors could be of
major importance in the clinical practice, as the statins
are prescribed to patients of various health conditions
and different settings of cardiovascular diseases.
Conclusions
The presented yeast expression system is suitable for
studying the effects of HMG-CoA reductase inhibitors
on various cellular processes, such as sterol biosynthesis,
gene expression and protein levels. We have shown that
the statins differ in their potency of action on gene ex-
pression, protein levels and lipid content. They induce
expression of genes from the main sterol biosynthesis
pathway. Genes from the pathways branching off the
main one appear to be less susceptible to upregulation.
Statin treatment substantially reduces the overall level of
cell sterols (depending on the statin, between 3-fold and
almost 8-fold), with the final product ergosterol being
less affected than its precursors.
Methods
Yeast strains and plasmids
All the yeast strains used in this study were S. cerevisiae
strains in the BY4742 background. Haploid yeast strain
H was derived from MB03-1D in which double deletion
of both genes encoding yeast HMG-CoA reductases,
hmg1Δ and hmg2Δ, was complemented by expression of
human HMGR gene introduced on the YEp351 plasmid
[11,18]. Additionally, strains Y1 and Y2 were constructedin which the hmg1Δ hmg2Δ double deletion was com-
plemented by yeast HMG1 or HMG2 genes, respectively,
introduced on YEp351 plasmid.
The YEp351 plasmid derivative for expression of the
human HMG-CoA reductase was made in the follo-
wing way. The SacI – SalI DNA fragment from pUG36
containing human HMGR gene [11] fused with an N-
terminal yeGFP (yeast-enhanced green fluorescent pro-
tein) tag, under the control of the yeast MET25 promoter,
was inserted into the YEp351 yeast expression plasmid.
To construct plasmid pYH1 for the expression of yeast
HMG1 gene, the HMG1 gene was amplified by PCR
with the following primers: F-SpeI-HMG1 5′-CTAG
ACTAGTATGCCGCCGCTATTCAAGG-3′ and R-Bam
HI-HMG1 5′-CGCGGATCCTTAGGATTTAATGCAG
GTGACG-3′ containing recognition sequences for SpeI
and BamHI restriction enzymes. The amplified DNA
fragment was cloned into pJet1.2 (Fermentas). The
resulting plasmid was digested with SpeI and BamHI,
and the obtained fragment was inserted into the SpeI-
BamHI sites of the pUG36 yeast expression vector
(Guldener and Hegemann, unpublished data) to obtain
the pYH1 construct. pYH1 was digested with SacI and
SalI, and the obtained fragment was inserted into the
SacI-SalI sites of the YEp351 expression vector to give a
construct encoding yeast HMG1 reductase fused with an
N-terminal yeGFP (yeast-enhanced green fluorescent pro-
tein) tag, under the control of the yeast MET25 promoter.
To construct plasmid pYH2 for expression of yeast
HMG2 gene, the HMG2 gene was amplified by PCR
with the following primers: F-BamHI-HMG2 5′-CG
GGATCCATGTCACTTCCCTTAAAAACGAT-3′ intro-
ducing a BamHI site before the START codon and R-
HMG2 5′-TTATAATAATGCTGAGGTTTTAC-3′. The
amplified DNA fragment was cloned into pJet1.2
(Fermentas). The resulting plasmid served as a template
for PCR amplification of the HMG2 sequence with add-
itional SmaI and SalI flanking sequences, for which
primers F-SmaI-BamHI-HMG2 5′-TCCCCCGGGCGGG
ATCCATGTCAC-3′ and R-SalI-HMG2 5′-ACGCGTC
GACTTATAATAATGCTGAGGTT-3′ were used. The
amplified DNA fragment was cloned into pJet 1.2
(Fermentas). The resulting plasmid was digested with
SmaI and SalI, and the obtained fragment was inserted
into the SmaI-SalI sites of the pUG36 yeast expression
vector to obtain the pYH2 construct. pYH2 was digested
with SacI and SalI, and the obtained fragment was
inserted into the SacI-SalI sites of the YEp351 expres-
sion vector to give a construct encoding yeast HMG2 re-
ductase gene fused with an N-terminal yeGFP tag, under
the control of the yeast MET25 promoter.
In order to obtain the H COQ3-HA strain the COQ3
ORF was tagged at the 3′ end with a sequence encoding
the 6HA epitope in the BY4742 strain. The 6HA epitope
Table 2 Primer sequences and qRT-PCR conditions




ERG10 F: 5′-GTCTGTGCATCCGCTATGAA-3′ 61 124
R: 5′-CTGCTGGCATGTAGTATGGT-3′
ERG13 F: 5′-TGGTAGAGACGCCATTGTAG-3′ 61 153
R: 5′-GCGTGTTCCATGTAAGAAGC-3′
HMGR F: 5′-ATGCTCACAGTCGCTGGATA-3′ 61 199
R: 5′-ACAGCCAGAAGGAGAGCTAA-3′
HMG1 F: 5′-CCGTATCCATGCCATCCATC-3′ 61 158
R: 5′-GACGGCACAGGCAACTATTC-3′
HMG2 F: 5′-CGCCATGCTTGATCTTCTCG-3′ 61 121
R: 5′-GGAGCACAGAGACAGTTCAC-3′
FPP1 F: 5′-TACAACACTCCAGGCGGTAA-3′ 61 166
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GAC-3′ and rTagCoq3 5′-CTGTACGTGAAAAAGTG
TATATATATATATTTATATAAGAAGATATTTACAGT
CAGATACCTACTTTTCGTTTGATTTCAATCGATGA
ATTCGAGCTCG-3′) were designed as previously re-
ported [29], except they both contained 80 bases of
homology to the designated site of recombination. The
PCR product was transformed to the BY4742 strain. The
correctness of the 6HA epitope tagging was then con-
firmed by colony PCR and Western blot analysis of
hygromycin resistant transformants. Selected transfor-
mant was crossed with the H strain and the obtained
diploids were sporulated and dissected on complete
medium. For further analysis spore clones that were
hygromycin and geneticin resistant, and contained ap-
propriate auxotrophy markers were selected. They were
confirmed by colony PCR and Western blot analysis.
The obtained H COQ3-HA strain (Mat a his3Δ1 leu2Δ0
lys2Δ0 ura3Δ0 hmg1Δ::kanMX4:HIS3 hmg2Δ::kanMX4
[pMET25-yeGFP-hHMGR/LEU]) which expressed func-
tional, HA-tagged Coq3 protein.
The pR7-HA plasmid for expression of HA-Rer2p [30]
was kindly provided by Prof. Akihiko Nakano from the
RIKEN Institute (Japan).R: 5′-CATCGGCGACCAAGAAGTAA-3′
ERG1 F: 5′-GTGTTATCGGTGACGCTCCTA-3′ 61 122
R: 5′-TTCACGGTCGCTGAAGTCTA-3′
ERG6 F: 5′-AAGACCTGGCGGACAATGAT-3′ 61 197
R: 5′-AGCAGCAGTAACTTCCTTGG-3′
ERG3 F: 5′-TCACGGCTAGTCTCAGCTAC-3′ 61 134
R: 5′-AACGGTCAACATCGACATCC-3′
BTS1 F: 5′-TAGGGGACAAGGCTTGGATA-3′ 61 168
R: 5′-ACCAACGAATGGCCGTGG TG-3′
COQ2 F: 5′-GTGTCTCGGCTGCCTAAGAA-3′ 61 198
R: 5′-GCCAGCACCTCTCATTACCA-3′
COQ3 F: 5′-AGTGAGCGTCTTGGATGTTG-3′ 61 183
R: 5′-TCCAGAGCCTTGCACTCATA-3′Chemicals and media
Solutions of various statins were prepared as follows: the
active substances were extracted from medicine tablets
using 0.5% dodecyl sodium sulfate in 0.01 M sodium
phosphate pH 7.0 buffer according to The United States
Pharmacopoeia USP26. Simvastatin, atorvastatin, fluvas-
tatin and rosuvastatin were extracted as above from
Zocor® (Merck & Co., Inc., Whitehouse Station, NJ,
USA), Atorvox® (Pliva Krakow, Zakłady Farmaceutyczne
S.A), Lescol® (Novartis Pharma GmbH) and Crestor®
(AstraZeneca AB, Sweden) tablets, respectively. Stock
solutions at 10 mg/ml were stored at −20°C. The media
and the genetic and microbiological techniques were es-
sentially as in [31].CAT5 F: 5′-TGGCTTGTACTGAAGCTGTC-3′ 61 195
R: 5′-CATGCTTGATAGCGGTGTCT-3′
RER2 F: 5′-GTCGATACGGCTACCGTGTT-3′ 61 133
R: 5′-ACTTACAGGCCAGCTCTCCA-3′
SEC59 F: 5′-AAGGTATGGCCGCATTCGTT-3′ 61 176
R: 5′-CTAGCACTCCACTCAGTGTA-3′
35S rRNA F: 5′-TCGACCCTTTGGAAGAGATG-3′ 60 203
R: 5′-CTCCGGAATCGAACCCTTAT-3′
F, R forward and reverse primers, respectively.Selection of statin dose for yeast treatment
In order to choose the proper dose of statins for yeast
experiments S. cerevisiae cultures in liquid minimal
media supplemented with increasing concentration of
statins, i.e. 3.125 μM, 6.25 μM, 25 μM, 100 μM and
200 μM were cultivated with shaking at 30°C. The op-
tical density of the cultures was measured at two-hour
intervals. Based on OD600 results growth curves of each
culture were plotted.Yeast growth and assay conditions
For testing growth in liquid cultures, inocula of S. cere-
visiae were added to liquid minimal media supple-
mented with one of the statins or buffer as a negative
control. Cultures were grown with shaking at 30°C and
OD600 was measured after 13 h and then every two
hours. Each culture was assayed in triplicate and the re-
sults were averaged.
RNA isolation and reverse transcription
Inocula of S. cerevisiae cells expressing HMGR genes
were added to liquid minimal media supplemented with
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with shaking at 30°C and collected after 24 h. Total
RNA was isolated from yeast cells using the MagNA
Pure Compact RNA Isolation Kit (Roche, Germany).
Reverse transcription (RT) was performed in dupli-
cate using the QuantiTect Reverse Transcription Kit
(QIAGEN, Germany), according to the manufactu-
rer’s recommendations.
mRNA quantification
Quantification of mRNA for the genes encoding en-
zymes of the mevalonate and sterol biosynthesis path-
way: ERG10, ERG13, HMGR, FPP1, ERG1, ERG6 and
ERG3, and of the nonsterol isoprenoid pathways: BTS1,
COQ2, COQ3, CAT5, RER2 and SEC59 was carried out
using Real-time Polymerase Chain Reaction (PCR).
qPCR amplification was performed using a LightCycler
1.5 and LightCycler FastStart DNA Master SYBR Green
I (Roche Diagnostics GmbH, Germany), according to the
manufacturer’s instructions. The Pfaffl model [32] was
used to determine the relative expression ratio of a tar-
get gene between tested and control samples. This
method is based on the mean CP deviation of the con-
trol and sample groups, normalized to a reference tran-
script and with real-time PCR efficiency correction. The
relative expression software tool (REST-MCS© – version
2) [33] was used for calculations. Data normalization
was carried out in relation to the transcript of the house-
keeping 35S rRNA gene. The sequences of all primers
and the qPCR parameters are detailed in Table 2.
Western blot analysis
Protein extracts were prepared by alkaline lysis ac-
cording to [34]. The extracts were additionally sonica-
ted in a water bath for 5 minutes before SDS-PAGE.
YeGFP-tagged human HMGR protein was detected with
anti-GFP antibody (Roche) and secondary anti-mouse
HRP-conjugated antibody (DAKO). 6HA-tagged yeast
cis-prenyltransferase Rer2p and 3,4-dihydroxy-5-he-
xaprenylbenzoate-O-methyltransferase Coq3p proteins
were detected with anti-HA antibody (BAbCo) and sec-
ondary antibody as above. To normalize protein levels
between samples rabbit anti-Pma1 (a gift from Prof.
Ramon Serrano) or mouse anti-Vma2 and secondary
antibodies as above were used. The proteins were
detected using an enhanced chemiluminescent substrate
for detection of HRP (Thermo Scientific). The intensity
of bands was calculated with ImageQuant 5.2 software.
Lipid extraction
Yeast cells were harvested, washed with water, carefully
decanted, weighed and frozen. Thawed yeast were sus-
pended in a mixture of chloroform:methanol (1:1) and
homogenized by extensive vortexing in the presence of asilica gel powder (0.063–0.20 mm), yeast:silica gel 2:1,
w/w. The mixture was agitated overnight at room tem-
perature. The homogenate was centrifuged (10 min;
2500 rpm) and obtained pellet was extracted three more
times with chloroform:methanol (1:1). Pooled superna-
tants were dried with a stream of nitrogen and remai-
ning lipids were subjected to alkaline hydrolysis by
incubation in a mixture of 7.5% KOH in ethanol:water:
toluene (85:15:100, by vol.) for two hours at 95°C. The
progress of reaction was followed on TLC (Silica gel
60 F254 plates) with toluene:ethyl acetate (9:1) as a devel-
oping system. Lipids were visualized with iodine vapor.
Lipophilic, non-saponifiable products were extracted
with diethyl ether, extracts were washed with water, or-
ganic phase was evaporated to dryness in a stream of ni-
trogen and lipids were dissolved in hexane. Samples
were stored at −20°C prior to further analysis.
GC/MS analysis of sterols
Gas chromatography–mass spectrometry analysis of ste-
rols was performed without derivatization on a 7890A
gas chromatograph (Agilent Technologies) coupled with
a 5975C single quadrupole mass spectrometer (Agilent
Technologies) equipped with a triple-axis detector and
an electron ionization ion source. An HP 5-MS column
(30 m × 0.25 mm, 0.25 μm) was used. Oven temperature
was maintained at 150°C for 5 min, and was then
increased linearly to 300°C at a rate of 5°C/min. The
temperature of the injector and the transfer line was
250°C. Helium was used as a carrier gas at a flow rate of
1 ml/min in the constant flow mode. Mass spectra were
acquired in the scan mode (33 – 600m/z range). Sterols
were identified on the basis of their mass fragmentation
patterns by comparing their spectra with those collected
in the NIST Mass Spectral Program (NIST/EPA/NIH
Mass Spectral Library Version 2.0f, build Oct 8 2008).
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